{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:19:15Z","timestamp":1789802355123,"version":"4.0.1"},"reference-count":50,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The pharmacokinetics (PKs) of mycophenolic acid (MPA) exhibit considerable complexity and large variability. We developed a population pharmacokinetic (popPK) model to predict the complex PK of MPA by examining an absorption model. Forty\u2010two patients who had undergone renal transplantation were included in this study. popPK analysis, incorporating several absorption models, was performed using the nonlinear mixed\u2010effects modeling program NONMEM. The MPA area under the concentration\u2010time curve at 0\u201312\u2009h (AUC0\u201312) was simulated using the final model to calculate the recommended dose. The PK of MPA was adequately described using a two\u2010compartment model incorporating sequential zero\u2010 and first\u2010order absorption with lag time. Total body weight, renal function (RF), and posttransplantation day (PTD) were included as covariates affecting MPA PK. The final model estimates were 7.56, 11.6\u2009L\/h, 104.0\u2009L, 17.3\u2009L\/h, 169.0\u2009L, 0.0453, 0.283, and 1.95\u2009h for apparent nonrenal clearance, apparent renal clearance, apparent central volume of distribution, apparent intercompartmental clearance, apparent peripheral volume of distribution, absorption half\u2010life, lag time, and duration of zero\u2010order absorption, respectively. Simulation results showed that a dose regimen of 500\u20131000\u2009mg twice daily is recommended during the early posttransplantation period. However, dose reduction could be required with increased PTD and decreased RF. The complex PK of MPA was explained using an absorption model. The developed popPK model can provide useful information regarding individual dosing regimens based on PTD and RF.<\/jats:p>","DOI":"10.1111\/cts.70097","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T09:31:41Z","timestamp":1733304701000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population pharmacokinetic analysis identifies an absorption process model for mycophenolic acid in patients with renal transplant"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9283-9802","authenticated-orcid":false,"given":"Yuki","family":"Suzuki","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy Nihon University  Funabashi Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy Nagasaki University Hospital  Nagasaki Nagasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6111-8537","authenticated-orcid":false,"given":"Takahiko","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy Nihon University  Funabashi Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2493-9616","authenticated-orcid":false,"given":"Chika","family":"Ogami","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences University of Toyama  Toyama Toyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1473-5617","authenticated-orcid":false,"given":"Chihiro","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy Nihon University  Funabashi Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satofumi","family":"Iida","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy Nihon University  Funabashi Chiba Japan"},{"name":"Department of Clinical Pharmacology Yokohama University of Pharmacy  Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"To","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences University of Toyama  Toyama Toyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kitahara","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Graduate School of Medicine Yamaguchi University  Ube Yamaguchi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7967-2947","authenticated-orcid":false,"given":"Yasuhiro","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy Nihon University  Funabashi Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746010-00002"},{"issue":"6","key":"e_1_2_10_3_1","first-page":"281","article-title":"Immunosuppressive drugs after solid organ transplantation","volume":"71","author":"Sandwijk MS","year":"2013","journal-title":"Neth J Med"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000871"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199834060-00002"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07111009"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-014-1247-1"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00802-z"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01863.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0927-4"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/11536640-000000000-00000"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0593-6"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443040-00004"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-020-00319-y"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1881176"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181a23f1a"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04140.x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12426"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-022-00271-w"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1211\/0022357991776831"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00340"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009332813"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1064"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-009-9136-6"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13850"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.859351"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0687-9"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-018-0278-6"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200402000-00006"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9066-0"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.05.056"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.25"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13230"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23574"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.14227\/DT190112P52"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01813-16"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04353-8"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj466"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2023.2287168"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02860806"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.558644"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000370"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20071-3"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00531.x"},{"key":"e_1_2_10_46_1","unstructured":"Ministry of Health Labor and Welfare.CELLCEPT (mycophenolate mofetil) PRESCRIBING INFORMATION in Japanese. Accessed August 13 2024.https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/450045_3999017B1025_1_14"},{"key":"e_1_2_10_47_1","unstructured":"US Food and Drug Administration.CELLCEPT (mycophenolate mofetil) PRESCRIBING INFORMATION. Accessed August 13 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/050722s050 050723s050 050758s048 050759s055lbl.pdf"},{"key":"e_1_2_10_48_1","unstructured":"European Medicines Agency.CellCept (mycophenolate mofetil) SUMMARY OF PRODUCT CHARACTERISTICS. Accessed August 13 2024.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/cellcept\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90102-3"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/48.3.517"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.01983.x"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T15:37:23Z","timestamp":1735054643000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/cts.70097"],"URL":"https:\/\/doi.org\/10.1111\/cts.70097","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70097"}}